Pacira BioSciences (PCRX) Intangibles (2010 - 2026)

Pacira BioSciences' Intangibles history runs 14 years deep, the most recent figure standing at $353.2 million for Q1 2026.

• On a quarterly basis, Intangibles fell 18.79% year-over-year to $353.2 million in Q1 2026; TTM through Mar 2026 was $353.2 million, a 18.79% decrease from a year earlier, with the FY2025 full-year figure at $368.1 million, down 13.59% from the prior year.
• Intangibles eased to $353.2 million in Q1 2026 per PCRX's latest filing, from $368.1 million in the prior quarter.
• Across five years, Intangibles topped out at $609.6 million in Q1 2022 and bottomed at $353.2 million in Q1 2026.
• The 5-year median for Intangibles is $468.9 million (2024), against an average of $476.3 million.
• Across the five-year window, Intangibles soared 544.76% in 2022 and slipped 18.79% in 2026, its largest moves.
• Year by year, Intangibles stood at $540.5 million in 2022, then slipped by 10.6% to $483.3 million in 2023, then declined by 11.85% to $426.0 million in 2024, then dropped by 13.59% to $368.1 million in 2025, then declined by 4.04% to $353.2 million in 2026.
• Per Business Quant, the three latest PCRX Intangibles figures stand at $353.2 million (Q1 2026), $368.1 million (Q4 2025), and $382.4 million (Q3 2025).